search
Back to results

Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma Patients

Primary Purpose

Glaucoma

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Pulse Electrical Stimulation
Sponsored by
Nu Eyne Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glaucoma

Eligibility Criteria

19 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants must be 19 to 75 years of age, at the time of screening
  • Patients with normal tension glaucoma or open angle glaucoma
  • Patients with best-corrected visual acuity of 20/40 or more
  • Patients whose Mean Deviation(MD) value of visual field test is -6dB or less
  • Patients who have stable eye pressure of less than 20mmHg over the past 2 months
  • If glaucoma treatment is in progress, the type, dose, and form of drug for treatment are stable for more than 2 months
  • A person who has no pregnancy plan during the clinical trial period and has agreed to an effective contraceptive plan for WOCBP(Women of child bearing potential)

    • WONCBP(Women of non-child bearing potential) must meet at least one of the following criteria:

      1. Postmenopausal women who are at least 45 years old and had no menses for 24 consecutive months
      2. A woman who underwent hysterectomy of bilateral ovarian resection recorded by a doctor
    • All other female patients will be considered WOCBP.
  • A person who voluntarily agreed to participate in this clinical trial

Exclusion Criteria:

  • Ophthalmological and neurological diseases that can affect visual field test(e.g., optic neuritis, diabetic retinopathy, age-related macular degeneration, and the epiretinal membrane)
  • A person with a history of surgery related to eyeball excluding simple cataract surgery or orbital surgery such as orbital fracture
  • Those who have more than -6D of refractive errors
  • Those who have cataracts of ETDRS(Early Treatment Diabetic Retinopathy Study) grade 3 or higher
  • Those who have a history of trauma around the eyeball, such as an orbital fracture, etc.,
  • Patients with active malignancy or history of malignancy, except completely treated in situ carcinoma of the cervix, completely treated and resected non-metastatic squamous of basal cell carcinoma of the skin.
  • A person who recently(within 1 month before the clinical trial medical device is applied) suffered severe trauma or underwent major surgery
  • Pregnant or lactating women
  • Any other severe acute or chronic medical or psychological conditions
  • Those who can't understand or read the consent form of this clinical trial(e.g. illiterate or foreigners)
  • Any other cases that PI considers hard to participate in this clinical trial(e.g. heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use out clinical trial device or is prohibited from using it.)
  • In the case of participating in other clinical trials within 6 months prior to the time of obtaining the consent form
  • Subjects who are not suitable for the clinical trial, are likely to be in danger when participate in the study or interfere with the interpretation of the trial results.
  • Brain and neck implant or pacemaker including deep brain stimulation device. Implantable or wearable cardioverter defibrillator. (Dental implants are accepted.)

Sites / Locations

  • Department of Ophthalmology, Konkuk University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Glaucoma patients

Arm Description

Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).

Outcomes

Primary Outcome Measures

Changes in intraocular pressure
Check the change of intraocular pressure in the baseline, 2, 6, 12, 16 weeks
Changes in visual acuity
Check the change of visual acuity in the baseline, 2, 6, 12, 16 weeks
Changes in mean deviation (MD)
Check the change of mean deviation(MD) in the baseline, 2, 6, 12, 16 weeks
Changes in pattern standard deviation(PSD)
Check the change of pattern standard deviation(PSD) in the baseline, 2, 6, 12, 16 weeks
Changes in visual field index(VFI)
Check the change of visual field index(VFI) in the baseline, 2, 6, 12, 16 weeks

Secondary Outcome Measures

Changes in parapapillary retinal nerve fiber layer thickness (RNFLT) using optical coherence tomography(OCT)
Check the change of parapapillary retinal nerve fiber layer thickness(RNFLT) in the baseline, 6, 16 weeks
Changes in Laminar cribrosa (LC) depth using optical coherence tomography(OCT)
Check the change of Laminar cribrosa(LC) depth in the baseline, 6, 16 weeks
Changes in macular ganglion cell-inner plexiform layer thickness (GCIPLT) using optical coherence tomography(OCT)
Check the change of macular ganglion cell-inner plexiform layer thickness(GCIPLT) in the baseline, 6, 16 weeks
Changes in circumpapillary vessel density (cpVD) using Optical coherence tomography angiography(OCT-A)
Check the change of circumpapillary vessel density(cpVD) in the baseline, 6, 16 weeks
Changes in macular vessel density (mVD) using Optical coherence tomography angiography(OCT-A)
Check the change of macular vessel density(mVD) in the baseline, 6, 16 weeks
Changes in N95 amplitude using pattern Electroretinogram(ERG)
Check the change of N95 amplitude in the baseline, 6, 16 weeks
Changes in N95 latency using pattern Electroretinogram(ERG)
Check the change of latency in the baseline, 6, 16 weeks
Changes in Glaucoma Quality of Life-15 (GQL-15)
Check the change of Glaucoma Quality of Life-15(GQL-15) score in the baseline, 6, 16 weeks

Full Information

First Posted
November 2, 2021
Last Updated
September 6, 2023
Sponsor
Nu Eyne Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05159414
Brief Title
Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma Patients
Official Title
A Single Center, Open-label, Exploratory Study to Evaluate the Efficacy and Safety of the Application of Pulse Electrical Stimulation Around the Eye in Glaucoma Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
May 4, 2021 (Actual)
Primary Completion Date
January 12, 2023 (Actual)
Study Completion Date
January 12, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nu Eyne Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study aims to evaluate the efficacy and safety of applying pulse electrical stimulation around eyes of glaucoma patients.
Detailed Description
Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Glaucoma patients
Arm Type
Experimental
Arm Description
Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
Intervention Type
Device
Intervention Name(s)
Pulse Electrical Stimulation
Intervention Description
Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
Primary Outcome Measure Information:
Title
Changes in intraocular pressure
Description
Check the change of intraocular pressure in the baseline, 2, 6, 12, 16 weeks
Time Frame
baseline, 2, 6, 12, 16 weeks
Title
Changes in visual acuity
Description
Check the change of visual acuity in the baseline, 2, 6, 12, 16 weeks
Time Frame
baseline, 2, 6, 12, 16 weeks
Title
Changes in mean deviation (MD)
Description
Check the change of mean deviation(MD) in the baseline, 2, 6, 12, 16 weeks
Time Frame
baseline, 2, 6, 12, 16 weeks
Title
Changes in pattern standard deviation(PSD)
Description
Check the change of pattern standard deviation(PSD) in the baseline, 2, 6, 12, 16 weeks
Time Frame
baseline, 2, 6, 12, 16 weeks
Title
Changes in visual field index(VFI)
Description
Check the change of visual field index(VFI) in the baseline, 2, 6, 12, 16 weeks
Time Frame
baseline, 2, 6, 12, 16 weeks
Secondary Outcome Measure Information:
Title
Changes in parapapillary retinal nerve fiber layer thickness (RNFLT) using optical coherence tomography(OCT)
Description
Check the change of parapapillary retinal nerve fiber layer thickness(RNFLT) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in Laminar cribrosa (LC) depth using optical coherence tomography(OCT)
Description
Check the change of Laminar cribrosa(LC) depth in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in macular ganglion cell-inner plexiform layer thickness (GCIPLT) using optical coherence tomography(OCT)
Description
Check the change of macular ganglion cell-inner plexiform layer thickness(GCIPLT) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in circumpapillary vessel density (cpVD) using Optical coherence tomography angiography(OCT-A)
Description
Check the change of circumpapillary vessel density(cpVD) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in macular vessel density (mVD) using Optical coherence tomography angiography(OCT-A)
Description
Check the change of macular vessel density(mVD) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in N95 amplitude using pattern Electroretinogram(ERG)
Description
Check the change of N95 amplitude in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in N95 latency using pattern Electroretinogram(ERG)
Description
Check the change of latency in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in Glaucoma Quality of Life-15 (GQL-15)
Description
Check the change of Glaucoma Quality of Life-15(GQL-15) score in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must be 19 to 75 years of age, at the time of screening Patients with normal tension glaucoma or open angle glaucoma Patients with best-corrected visual acuity of 20/40 or more Patients whose Mean Deviation(MD) value of visual field test is -6dB or less Patients who have stable eye pressure of less than 20mmHg over the past 2 months If glaucoma treatment is in progress, the type, dose, and form of drug for treatment are stable for more than 2 months A person who has no pregnancy plan during the clinical trial period and has agreed to an effective contraceptive plan for WOCBP(Women of child bearing potential) WONCBP(Women of non-child bearing potential) must meet at least one of the following criteria: Postmenopausal women who are at least 45 years old and had no menses for 24 consecutive months A woman who underwent hysterectomy of bilateral ovarian resection recorded by a doctor All other female patients will be considered WOCBP. A person who voluntarily agreed to participate in this clinical trial Exclusion Criteria: Ophthalmological and neurological diseases that can affect visual field test(e.g., optic neuritis, diabetic retinopathy, age-related macular degeneration, and the epiretinal membrane) A person with a history of surgery related to eyeball excluding simple cataract surgery or orbital surgery such as orbital fracture Those who have more than -6D of refractive errors Those who have cataracts of ETDRS(Early Treatment Diabetic Retinopathy Study) grade 3 or higher Those who have a history of trauma around the eyeball, such as an orbital fracture, etc., Patients with active malignancy or history of malignancy, except completely treated in situ carcinoma of the cervix, completely treated and resected non-metastatic squamous of basal cell carcinoma of the skin. A person who recently(within 1 month before the clinical trial medical device is applied) suffered severe trauma or underwent major surgery Pregnant or lactating women Any other severe acute or chronic medical or psychological conditions Those who can't understand or read the consent form of this clinical trial(e.g. illiterate or foreigners) Any other cases that PI considers hard to participate in this clinical trial(e.g. heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use out clinical trial device or is prohibited from using it.) In the case of participating in other clinical trials within 6 months prior to the time of obtaining the consent form Subjects who are not suitable for the clinical trial, are likely to be in danger when participate in the study or interfere with the interpretation of the trial results. Brain and neck implant or pacemaker including deep brain stimulation device. Implantable or wearable cardioverter defibrillator. (Dental implants are accepted.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Youn Hye Jo, Ph. D
Organizational Affiliation
Konkuk University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Ophthalmology, Konkuk University Medical Center
City
Seoul
ZIP/Postal Code
05030
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma Patients

We'll reach out to this number within 24 hrs